RBC
CLB icon

Roble Belko & Company’s Core Laboratories CLB Stock Holding History

Roble Belko & Company’s Portfolio CLB Stock Details CLB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-82
Closed -$9K – 308
2017
Q1 		$9K Hold
82
– – ﹤0.01% 205
2016
Q4 		$10K Buy
+82
New +$9.08K 0.01% 204

Other funds holding CLB

ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SGA
Sustainable Growth Advisers Stamford, Connecticut $10.2B AUM 1.48% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
WP
Wedgewood Partners St Louis, Missouri $484M AUM 16.04% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Roble Belko & Company's CLB Position: Q2 2017 in Review

Roble Belko & Company sold out of Core Laboratories (CLB) in Q2 2017, closing a stake of 82 shares — an estimated $9K sold.

Roble Belko & Company first reported a position in CLB in Q4 2016 and held it in 2 quarters. The position peaked at $10K in Q4 2016. 360 funds tracked by Wall St. Rank hold CLB as of Q2 2017.

  • Roble Belko & Company reported no remaining Core Laboratories position as of Q2 2017 after selling out during the quarter.
  • Roble Belko & Company sold 82 Core Laboratories shares in Q2 2017, an estimated $9K.
  • Roble Belko & Company first reported a position in Core Laboratories in Q4 2016 and held it in 2 quarters.
  • Roble Belko & Company's Core Laboratories position peaked at $10K in Q4 2016.
  • 360 funds tracked by Wall St. Rank held Core Laboratories as of Q2 2017.

Based on Roble Belko & Company's 13F filing for Q2 2017, filed 11 Aug 2017.